Article Text

Download PDFPDF

  1. Trevor Pickersgill1,
  2. Gayle Sheppard1,
  3. Gail Clayton1,
  4. Neil Robertson2
  1. 1Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales
  2. 2School of Medicine, Cardiff University


The decision to commence disease modifying treatments (DMTs) for MS patients was once straightforward. Since the advent of monoclonal antibodies and the first oral DMT(soon to be several) our armamentarium is increasingly complex.Guiding patients through the choices;ensuring guideline adherence;personalising risk assessment and ensuring NHS budgets are spent justifiably are paramount.

We have piloted an ‘MS DMT MDT’.For 12 months treatment planning has been done by the full MS Team.

In 13 MDTs 39 decisions were made on 36 patients (26 female); mean age (range) 39 (17–69) years.

15/36 (41.7%) were treatment naïve. Of these 9 were offered first-line injectables; 3 a choice of injectable/monoclonal; 2 monoclonals and 1 was declined. Ongoing therapies are:

  • injectable – 5 (33.3%)

  • Natalizumab – 1 (6.7%)

  • Alemtuzumab – 3 (20.0%)

  • No DMT – 6 (40.0%)

21/36 (58.3%) were concurrently or previously on DMTs, 8 had used 2 or more. The median (range) duration of prior exposure was 2.31 (0.02–5.27) years.

The MS DMT MDT has enabled decision making to be increasingly robust, evidence-based and formally recorded. The MDT has the support of NHS managers who are prospectively assured that only appropriate patients are treated. We propose that this model is adapted for other MS treatment centres.


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.